| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.1 | 0.6 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.098 | 0.6 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |